Answers are grounded in this paper and cite their sources.
Introduction: Prostate Imaging Reporting and Data System (PI-RADS) 3 ("equivocal") prostate magnetic resonance imaging (MRI) lesions pose a diagnostic challenge, particularly in non-referral settings with variable MRI quality. We evaluated whether prostate-specific antigen density (PSAD) and the Stockholm3 blood test can aid biopsy decisions for men with PI-RADS 3 lesions in a prospective, non-referral Swiss cohort. Methods: Retrospective analysis of a prospective registry at a non-referral urology practice in Switzerland. From 2023 to 2025, men with PSA >1.5 ng/mL or suspicious digital rectal examination underwent Stockholm3 testing, MRI, and MRI-fusion plus systematic prostate biopsy. Clinically significant prostate cancer (csPCa) was defined as the International Society of Urological Pathology (ISUP) grade ≥2. Diagnostic accuracy and decision curve analysis compared Stockholm3 (≥13%, ≥15%, and ≥18%) and PSAD thresholds (0.10, 0.15, and 0.20 ng/mL/cc) within the PI-RADS 3 subgroup. As continuous measures, PSAD demonstrated superior discrimination (area under the receiver operating characteristic curve: 0.751; 95% confidence interval: 0.46-0.95) than Stockholm3 (area under the receiver operating characteristic curve: 0.595; 95% confidence interval: 0.30-0.88), confirming higher overall diagnostic accuracy within the PI-RADS 3 subgroup. Decision curve analysis demonstrated higher net benefit for PSAD-based approaches. Conclusion: In non-referral practice, Stockholm3 did not reliably exclude csPCa among men with PI-RADS 3 lesions. PSAD-based triage, particularly at ≥0.15 ng/mL/cc, showed superior diagnostic utility and may support safe biopsy deferral in selected cases. Prospective validation in broader non-referral settings is warranted.
No takes yet. Share an insight, caveat, or question.
Arnold et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: